PDL BioPharma Seeks Ularitide Partner That Grants Rights To A Late-Stage Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
A more complicated partnership involving two clinical programs is taking more time to complete than a “ularitide-only” deal, the biotech says.
You may also be interested in...
PDL BioPharma Product Sales Up 25 Percent On Cardene Growth
Firm is focused on lifecycle management for Cardene as well as partnering opportunities for investigational drugs ularitide and Nuvion, CEO says.
PDL BioPharma Product Sales Up 25 Percent On Cardene Growth
Firm is focused on lifecycle management for Cardene as well as partnering opportunities for investigational drugs ularitide and Nuvion, CEO says.
Biogen Idec/PDL BioPharma Plan To Study Daclizumab As Monotherapy For MS
Phase II monotherapy trial for the monoclonal antibody will initiate in the second half of 2007, PDL tells “The Pink Sheet” DAILY.